Icotinib is the first oral inhibitor of epidermal growth factor receptor (EGFR), and it is prescribed for EGFR-positive non-small cell lung cancer (NSCLC) (Guan, He & Li, 2014; Tan et al., 2023). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.